Recent Finacing
Recent Raise
Intrommune develops an oral mucosal immunotherapy platform delivering precise food-protein doses via a toothpaste for daily toothbrushing desensitization, with lead candidate INT301 targeting peanut allergy and FDA pre-IND engagement.
